Dunad Therapeutics has struck a new multi-million dollar deal with Novartis
Biopharmaceutical company Dunad Therapeutics (Dunad) has annouced that it has entered into a strategic collaboration with Novartis, to develop orally bioavailable covalent and protein degrading small molecule drugs.
Professor Patrick Gunning is the Co-founder, acting CEO and Chief Scientific Officer of Dunad Therapeutics and is thrilled to have entered this collaboration with Novartis.
Here are a few stories in all major biotech news outlets following the big announcement on
Gunning Group receives $100,000 grant from Brain Cancer Canada
A pioneering approach led by Prof. Patrick Gunning at the University of Toronto, leveraging advanced medicinal chemistry to help develop potential treatments against Glioblastoma (GBM) and other high-grade gliomas (HGGs), has received a $100,000 grant from Brain Cancer Canada on Giving Tuesday. The research has identified an approach to potentially breaching barriers that are holding back effective brain cancer therapies. Brain Cancer Canada has made these funds available tha
Patrick Gunning recognized with Connaught Innovation Award
Professor Patrick Gunning of the department of chemical and physical sciences at the University of Toronto Mississauga has received a Connaught Innovation Award for his team's work on HDAC6 inhibitors to treat hematological malignancies – cancers that affect the blood, bone marrow, and lymph nodes. A Canada Research Chair in Medicinal Chemistry and the director of the Centre for Medicinal Chemistry, Gunning has founded three pharmaceutical companies with more than $22 million
Our PhD graduate Aaron Cabral to pursue career in drug discovery
iAaron Cabral will earn his PhD in chemistry from the Unversity of Toronto’s Faculty of Arts & Science this week after focusing his research on developing new diagnostic methods for drug discovery research in oncology and neurodegenerative diseases. Under the supervision of Patrick Gunning, a professor in U of T Mississauga’s department of chemical and physical sciences, Cabral also worked on a platform for chemically “tuning” drugs to improve their stability and selectivity.
